{"meshTagsMajor":["Mastectomy, Segmental"],"meshTags":["Antineoplastic Agents, Hormonal","Breast Neoplasms","Combined Modality Therapy","Female","Humans","Lymph Nodes","Mastectomy, Segmental","Neoplasm Staging","Patient Selection","Prognosis","Quality of Life","Radiotherapy Dosage","Randomized Controlled Trials as Topic","Salvage Therapy","Survival Analysis","Treatment Outcome"],"meshMinor":["Antineoplastic Agents, Hormonal","Breast Neoplasms","Combined Modality Therapy","Female","Humans","Lymph Nodes","Neoplasm Staging","Patient Selection","Prognosis","Quality of Life","Radiotherapy Dosage","Randomized Controlled Trials as Topic","Salvage Therapy","Survival Analysis","Treatment Outcome"],"organisms":["9606","9606","9606"],"publicationTypes":["Journal Article","Review"],"abstract":"Several patient and tumor factors go into the decision process to determine whether a breast cancer patient is a good candidate for breast-conserving therapy. The patient must be seen by all disciplines before any therapeutic intervention. When used appropriately, breast-conserving therapy produces maximal disease control and improves quality of life in patients with early-stage breast cancer.","title":"Breast-conserving therapy (BCT) for early-stage breast cancer.","pubmedId":"14696083"}